Cytokinetics (NASDAQ:CYTK) Shares Purchased Rep. Gilbert Ray Cisneros, Jr.

by · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on June 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

  • Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
  • Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
  • Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
  • Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
  • Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
  • Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
  • Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
  • Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
  • Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.
  • Purchased $1,001 – $15,000 in shares of CECO Environmental (NASDAQ:CECO) on 6/30/2026.

Cytokinetics Price Performance

NASDAQ CYTK remained flat at $86.49 on Friday. The company had a trading volume of 2,022,530 shares, compared to its average volume of 2,483,229. Cytokinetics, Incorporated has a twelve month low of $32.89 and a twelve month high of $88.31. The stock has a market capitalization of $10.76 billion, a PE ratio of -12.64 and a beta of 0.42. The business has a 50-day moving average price of $74.97 and a two-hundred day moving average price of $67.74.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million for the quarter, compared to the consensus estimate of $8.52 million. During the same period in the previous year, the business earned ($1.36) earnings per share. The firm’s revenue for the quarter was up 1112.5% on a year-over-year basis. Sell-side analysts predict that Cytokinetics, Incorporated will post -6.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CYTK. Mizuho upped their target price on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, June 24th. Truist Financial set a $106.00 price objective on Cytokinetics in a research note on Tuesday, May 5th. Robert W. Baird set a $84.00 target price on shares of Cytokinetics in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a research note on Monday, April 20th. Finally, Morgan Stanley upped their price target on shares of Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and an average target price of $100.00.

Get Our Latest Report on Cytokinetics

Insider Transactions at Cytokinetics

In related news, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $59.62, for a total transaction of $447,150.00. Following the completion of the sale, the chief executive officer directly owned 407,830 shares in the company, valued at $24,314,824.60. This represents a 1.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,857 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $65.00, for a total value of $1,030,705.00. Following the transaction, the executive vice president owned 58,555 shares in the company, valued at approximately $3,806,075. The trade was a 21.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 143,985 shares of company stock worth $10,403,417 over the last ninety days. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Woodline Partners LP boosted its stake in shares of Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after purchasing an additional 1,435,422 shares in the last quarter. Norges Bank purchased a new position in Cytokinetics in the 4th quarter worth $51,281,000. Deep Track Capital LP raised its position in Cytokinetics by 17.8% in the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after purchasing an additional 650,000 shares during the period. Siren L.L.C. bought a new stake in Cytokinetics in the first quarter worth $40,466,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Cytokinetics by 151,987.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after purchasing an additional 565,393 shares during the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

See Also